The board of directors of MicroPort CardioFlow Medtech Corporation announced the following changes to the composition of the audit committee of the Company (the "Audit Committee"), the remuneration committee of the Company (the "Remuneration Committee") and the nomination committee of the Company (the "Nomination Committee"), with effect from December 15, 2025: Mr. Chen Guoming, a non-executive Director and the chairman of the Board, has been appointed as a member of the Audit Committee, and ceased to be a member of the Remuneration Committee and the chairperson of the Nomination Committee. Dr. Hu Bingshan, an independent non-executive Director, has been re-designated as the chairperson of the Nomination Committee, and appointed as a member of the Remuneration Committee, and ceased to be a member of the Audit Committee. Dr. Brian Chang, a non-executive Director, has been appointed as a member of the Nomination Committee.

The Board hereby announces that, with effect from December 15, 2025, the Board resolved to establish the strategy committee of the Board (the "Strategy Committee"). The establishment of the Strategy Committee aims to conduct researches and submit proposals regarding the long-term development strategies and major development decisions of the Company. The Strategy Committee consists of six members, including Dr. Brian Chang, Mr. Chen Guoming, Mr. Zhang Ruinian, Mr. Philippe Wanstok, Mr. Deng Aoyi and Dr. Hu Bingshan, and Dr. Brian Chang acts as the chairperson.

The Board hereby announces that, with effect from December 15, 2025, the Board resolved to establish the commercialization committee of the Board (the "Commercialization Committee"). The establishment of the Commercialization Committee aims to further optimize the planning and implementation of the Company's commercialization system, and to fully leverage on the guidance of the Commercialization Committee, so as to enhance the competitiveness edges of the Company's products in the market during commercialization. The Commercialization Committee consists of five members, including Mr. Chen Guoming, Dr. Brian Chang, Mr. Zhang Ruinian, Mr. Philippe Wanstok, and Ms. Wu Xia.

Mr. Chen Guoming acts as the chairperson.